secwatch.observer — SEC 8-K summary
======================================

Issuer:     Hepion Pharmaceuticals, Inc. (HEPA)
CIK:        0001583771
Form:       8-K
Filed at:   2024-01-03T23:59:59+00:00
Accession:  0001104659-24-000860
Event type: other_material
Sentiment:  negative
Materiality: 0.60
Item codes: 4.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Hepion Pharmaceuticals dismisses BDO, appoints Grassi as new auditor
--------------------------------------------------------------------

- BDO dismissed as independent auditor effective Jan 1, 2024; Grassi Advisors engaged to audit FY 2023 financials.
- BDO reports for FY 2021 and 2022 contained going-concern explanatory paragraph due to recurring losses and accumulated deficit.
- Material weaknesses in internal control over financial reporting identified in prior annual and quarterly reports.
- No disagreements with BDO on accounting principles or audit scope during the past two years.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583771/000110465924000860/0001104659-24-000860-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583771/000110465924000860/tm241750d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-000860

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer